Skip to main content
Journal cover image

LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells.

Publication ,  Journal Article
Haraguchi, S; Day, NK; Kamchaisatian, W; Beigier-Pompadre, M; Stenger, S; Tangsinmankong, N; Sleasman, JW; Pizzo, SV; Cianciolo, GJ
Published in: AIDS Res Ther
March 31, 2006

BACKGROUND: Co-infections of human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (M. Tb) are steadily increasing and represent a major health crisis in many developing countries. Both pathogens individually stimulate tumor necrosis factor-alpha (TNF) release from infected cells and TNF, in turn, enhances the replication of each. A recent report on a Phase I clinical trial suggested that etanercept (soluble TNF receptor) might be beneficial in treating HIV/M. Tb co-infected patients. We sought to determine if a small molecule inhibitor of TNF synthesis and activity could block replication of either organism and thus be a potential adjunct to existing drugs targeting these agents. RESULTS: LMP-420, a novel anti-inflammatory agent that inhibits TNF, was tested for HIV-1 inhibition both alone and in combination with AZT (3' -azido-3-deoxythymidine). LMP-420 alone was tested against M. Tb. HIV-1 infected human peripheral blood mononuclear cells (PBMC) or M. Tb-infected human alveolar macrophages (AM) were treated with a single dose of LMP-420 and viral or bacterial replication determined after 7 or 5 days respectively. Viral replication was determined from supernatant p24 levels measured by ELISA. M. Tb replication was determined by bacterial culture of macrophage lysates. LMP-420 alone inhibited HIV replication over 7 days with an IC50 of approximately 300 nM. Combination of LMP-420 with AZT doubled the level of HIV inhibition observed with AZT alone. LMP-420 alone inhibited the replication of virulent M. Tb by >80%, more than that observed with anti-TNF antibody alone. CONCLUSION: Inhibition of TNF with inexpensive, small-molecule, orally-active drugs may represent a useful strategy for enhancing the activity of currently-available antiviral and anti-M. Tb agents, particularly in those areas where co-infections with these pathogens act to synergistically enhance each other.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

AIDS Res Ther

DOI

EISSN

1742-6405

Publication Date

March 31, 2006

Volume

3

Start / End Page

8

Location

England

Related Subject Headings

  • Virology
  • 3202 Clinical sciences
  • 1107 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haraguchi, S., Day, N. K., Kamchaisatian, W., Beigier-Pompadre, M., Stenger, S., Tangsinmankong, N., … Cianciolo, G. J. (2006). LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells. AIDS Res Ther, 3, 8. https://doi.org/10.1186/1742-6405-3-8
Haraguchi, Soichi, Noorbibi K. Day, Wasu Kamchaisatian, Macarena Beigier-Pompadre, Steffen Stenger, Nutthapong Tangsinmankong, John W. Sleasman, Salvatore V. Pizzo, and George J. Cianciolo. “LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells.AIDS Res Ther 3 (March 31, 2006): 8. https://doi.org/10.1186/1742-6405-3-8.
Haraguchi S, Day NK, Kamchaisatian W, Beigier-Pompadre M, Stenger S, Tangsinmankong N, et al. LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells. AIDS Res Ther. 2006 Mar 31;3:8.
Haraguchi, Soichi, et al. “LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells.AIDS Res Ther, vol. 3, Mar. 2006, p. 8. Pubmed, doi:10.1186/1742-6405-3-8.
Haraguchi S, Day NK, Kamchaisatian W, Beigier-Pompadre M, Stenger S, Tangsinmankong N, Sleasman JW, Pizzo SV, Cianciolo GJ. LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells. AIDS Res Ther. 2006 Mar 31;3:8.
Journal cover image

Published In

AIDS Res Ther

DOI

EISSN

1742-6405

Publication Date

March 31, 2006

Volume

3

Start / End Page

8

Location

England

Related Subject Headings

  • Virology
  • 3202 Clinical sciences
  • 1107 Immunology